Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Entereg Gets Cautious Approval Recommendation; More Safety Data Needed

Executive Summary

FDA's Gastrointestinal Drugs Advisory Committee overwhelmingly found that GlaxoSmithKline/ Adolor's Entereg (alvimopan) demonstrates convincing efficacy, leading to a positive recommendation for approval, but the panel also expressed concerns about the limited scope of safety data and an inadequate risk management plan
Advertisement

Related Content

Entereg’s REMS To Assess Off-Label Use In Quarterly Reports To FDA
Entereg’s REMS To Assess Off-Label Use In Quarterly Reports To FDA
FDA’s Strongest REMS To Date: Entereg Approved With Controlled-Distribution
FDA’s Strongest REMS To Date: Entereg Approved With Controlled-Distribution
FDA Requests Entereg Failed Study Data, Adolor Says
Advertisement
UsernamePublicRestriction

Register

PS049229

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel